Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS vs EDARBI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Treatment of hypertension (FDA-approved),Cardiovascular risk reduction in patients unable to take ACE inhibitors (off-label)
Treatment of hypertension,Off-label: Diabetic nephropathy, heart failure
40-80 mg orally once daily.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Telmisartan is metabolized by glucuronidation via UGT1A3 and UGT2B7; minimal CYP450 metabolism.
Primarily metabolized by CYP2C9 and CYP3A4; undergoes dehydrogenation and decarboxylation.
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Highly bound (>99.5%), primarily to albumin and α1-acid glycoprotein. Binding is saturable at high concentrations but clinically not significant at therapeutic doses.
High (>99% bound to serum proteins, mainly albumin).
Apparent volume of distribution: approximately 500 L (about 7 L/kg), indicating extensive extravascular distribution.
Approximately 0.9 L/kg (total Vdss of about 86 L), indicating extensive distribution into tissues.
Oral bioavailability is variable, approximately 40-60% (mean 50%) due to first-pass metabolism. Food reduces bioavailability by about 20%, but clinical effect is not significantly altered.
Absolute bioavailability is about 15% due to extensive first-pass metabolism (CYP2C9, UGT1A3).
No dose adjustment required for GFR ≥30 m L/min. Not studied in GFR <30 m L/min or dialysis; use caution.
No dose adjustment is required for patients with mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease (ESRD), caution is advised; no specific dosing recommendations are available due to limited data. Avoid use in patients undergoing dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), maximum dose is 40 mg once daily.
No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A). For moderate hepatic impairment (Child-Pugh class B), the recommended starting dose is 40 mg once daily; maximum dose is 40 mg once daily. EDARBI should not be used in patients with severe hepatic impairment (Child-Pugh class C).
Safety and efficacy not established in pediatric patients (<18 years).
Safety and efficacy in pediatric patients (<18 years) have not been established. Therefore, no dosing recommendation is provided.
No specific dose adjustment needed; start at lower end of dosing range (40 mg) due to possible increased sensitivity.
No dose adjustment is required for elderly patients (≥65 years). However, as with all patients, initiate at 40 mg once daily; consider cautious titration due to potential greater sensitivity and increased risk of hypotension.
No FDA boxed warning.
No FDA boxed warnings.
Fetal toxicity: Use in pregnancy can cause injury and death to the fetus; discontinue when pregnancy is detected.,Hypotension in volume- or salt-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant K+ supplements/sparing diuretics,Avoid coadministration with aliskiren in patients with diabetes
Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy occurs,Hypotension in volume-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk in patients with renal impairment or on potassium-sparing diuretics,Avoid use in patients with bilateral renal artery stenosis
Concomitant use with aliskiren in patients with diabetes mellitus,Known hypersensitivity to telmisartan or any component,Pregnancy (second and third trimesters)
Concomitant use with aliskiren in patients with diabetes,Hypersensitivity to edarbi or any component,Pregnancy
No specific food restrictions. Avoid salt substitutes containing potassium chloride. Maintain consistent dietary habits to avoid fluctuations in blood pressure. Grapefruit juice has no known interaction but other drugs may be affected; consult pharmacist for all medications.
No significant food interactions. May be taken with or without food. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) and salt substitutes containing potassium, especially in patients with renal impairment or those on concomitant RAAS inhibitors or potassium-sparing diuretics.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester exposure does not appear to increase the risk of congenital anomalies, but should be avoided due to potential unknown risks. Oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and hyperkalemia are risks associated with second and third trimester exposure.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal renal damage, oligohydramnios, and skull ossification defects. Second and third trimester exposure: Increased risk for oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and anuria. Use is contraindicated in pregnancy, especially in second and third trimesters.
No data on the excretion of telmisartan into human milk are available. Telmisartan is excreted in the milk of lactating rats. Because of the potential for adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
No data on azilsartan medoxomil (EDARBI) excretion in human milk; effects on the breastfed infant and milk production are unknown. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio unknown.
No dose adjustment guidelines are available due to lack of pharmacokinetic studies in pregnancy. However, due to the risks associated with RAS inhibition, telmisartan should be discontinued as soon as pregnancy is detected, and alternative antihypertensive therapy should be initiated if needed.
EDARBI is not recommended during pregnancy; if pregnancy is detected, discontinue as soon as possible. No specific dose adjustments have been established for use in pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data are available to guide dosing.
Monitor renal function and serum potassium before and during therapy, especially in patients with renal impairment or on potassium-sparing diuretics. May cause a rise in serum creatinine; usually minor and reversible. Avoid use in patients with biliary obstructive disorders or severe hepatic impairment due to primarily biliary excretion. Can be used with or without food; consistency recommended to avoid variability in absorption. Combination with aliskiren is contraindicated in diabetes. Adjust dose in patients with hepatic impairment; initial dose 40 mg once daily.
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) with high receptor affinity and a long half-life (~11 hours), allowing once-daily dosing. It is a prodrug that is rapidly hydrolyzed to the active moiety azilsartan. Onset of action within 2 weeks; maximum effect may take 4-6 weeks. Monitor renal function and serum potassium, especially in patients with renal impairment, diabetes, or those taking NSAIDs or potassium-sparing diuretics. Avoid use in pregnancy (category D). Dose adjustment recommended for patients with hepatic impairment (Child-Pugh class B).
Take this medication exactly as prescribed, usually once daily, with or without food. Try to take it at the same time each day.,Do not stop taking this medicine without consulting your doctor, even if you feel well. High blood pressure often has no symptoms.,If you have a pregnancy potential, use effective contraception and notify your doctor immediately if you become pregnant. This drug can harm an unborn baby.,Avoid alcohol and use caution when driving or operating machinery until you know how this medicine affects you, as dizziness may occur.,Do not use salt substitutes containing potassium without your doctor's approval. This medication may increase your potassium levels.,Stay adequately hydrated, especially during exercise or in hot weather, to prevent low blood pressure. Dehydration may increase the risk of low blood pressure.,Report any signs of infection (fever, sore throat) or swelling of the face, lips, or tongue, which may indicate a serious allergic reaction.,Keep all appointments for blood pressure checks and lab work (kidney function and potassium levels).
Take exactly as prescribed, usually once daily, with or without food.,Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms such as dizziness, fainting, rapid heartbeat, or signs of kidney problems (e.g., swelling, decreased urination).,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not double the dose.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS vs EDARBI, answered by our medical review team.
MICARDIS is a Angiotensin II Receptor Blocker that works by Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.. EDARBI is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS and EDARBI depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS is: 40-80 mg orally once daily.. The standard adult dose of EDARBI is: EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS and EDARBI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester expos. EDARBI is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.